Uric acid is usually handed to patients as a single number, but the published data tie it to a wider metabolic and inflammatory pattern. In a cross-sectional analysis of 3,288 U.S. adults from NHANES 2007–2018, participants in the highest quartile of a combined uric acid–inflammation–metabolism (UIM) score had 2.63 times the odds of osteoarthritis compared with the lowest quartile (adjusted OR 2.63, 95% CI 1.47–4.72).1
That is an association measured at one point in time, not evidence that lowering uric acid prevents osteoarthritis. It is a reason to read the number in context, which is how we use it: as one input to a conservative-first plan rather than a target on its own.
Key takeaways
- The published risk score treats uric acid as one of seven variables, not as a stand-alone marker.
- In NHANES data, hyperuricemia was associated with substantially higher odds of metabolic syndrome.
- Gout burden in working-age adults is large globally, which is why the pattern shows up in clinic so often.
- All of the above is associational. None of it establishes that treating a lab value changes a joint outcome.
- At Regen.MD, metabolic work comes before structural work. See the Biological Baseline Program.
Why uric acid is read alongside metabolic markers
The seven variables in the UIM score
The UIM score was built by LASSO logistic regression from 14 candidate variables, of which seven were retained: uric acid, eGFR, serum creatinine, hs-CRP, waist circumference, HDL cholesterol, and BMI.1 Kidney handling, inflammatory status, and body composition all sit inside the model, which is precisely the point.
In that analysis the uric acid dimension contributed most to the score at 70.50%, followed by the metabolic dimension at 26.92% and the inflammatory dimension at 2.58%.1 The combined score discriminated better than any individual biomarker, with an AUC of 0.707.1
What the score does and does not show
The discovery cohort was 3,288 U.S. adults from NHANES 2007–2018, with external validation in a cohort of 859 patients at a Chinese provincial hospital.1 Both are cross-sectional. The score is presented by its authors as a stratification tool for osteoarthritis prevalence, not as a causal mechanism and not as a treatment target.
Hyperuricemia and metabolic syndrome
What NHANES 2013–2018 found
A separate NHANES analysis of 6,432 U.S. adults, weighted to represent roughly 94.7 million non-institutionalized civilians, examined hyperuricemia against metabolic syndrome. Unadjusted, individuals with hyperuricemia (above 7.0 mg/dL in men and 6.0 mg/dL in women) were 3.19 times more likely to have metabolic syndrome than those with normal uric acid.2
The association survived adjustment. In two further regression models controlling for previously identified metabolic syndrome risk factors, those with hyperuricemia were 1.89 and 1.34 times more likely to have metabolic syndrome.2 The effect shrinks under adjustment, which is worth noticing rather than glossing over.
How common gout is in working-age adults
Globally in 2021, there were an estimated 6.08 million new gout cases and 32.7 million prevalent cases among people aged 15 to 64, according to a Global Burden of Disease 2021 analysis released as a preprint.3 Men in that age band had roughly three times the prevalence of women.3
This is a burden estimate, not a clinical finding about any individual, and it comes from a preprint that has not completed peer review. We include it because it explains why the uric acid conversation comes up so frequently in working-age patients, not because it tells us anything about your knee.
How Regen.MD approaches this
The Clinical Evaluation comes first
Entry is a paid, physician-led Clinical Evaluation with Dr. Gurpreet Singh Padda, MD, MBA, MHP: a review of history, imaging, and metabolic data, ending in a written roadmap. The question we are trying to answer is whether joint symptoms are being driven by structure, by metabolic terrain, or by both.
Metabolic optimization before structural work
The Biological Baseline Program runs fasting insulin, HbA1c, hs-CRP, lipid fractionation, and a hormone profile, along with coronary artery calcium scoring and vascular-age imaging. It is the mandatory first phase for every structural patient here: the metabolic bottleneck is corrected before any joint, spine, or nerve procedure is scheduled. Background on why we treat inflammation as terrain is in The Metabolic Bottleneck.
Where orthobiologics fit
Orthobiologics at Regen.MD include intra-articular and tendon platelet-rich plasma, intraosseous and subchondral PRP, bone marrow aspirate concentrate, Lipogems, and intradiscal orthobiologics. For advanced knee osteoarthritis, PRP is framed as , a safe bridge therapy prior to joint replacement. None of these regrows cartilage, and we will not describe them that way. The full scope is set out under orthobiologics.
Where conservative measures have genuinely been exhausted, surgery is on the table and is discussed on its merits. Dr. Padda is a surgeon; surgery is simply not the opening move.
Have the lab pattern and the joint findings read together
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call (314) 295-3000 or text (314) 886-5902.
Frequently Asked Questions
Is uric acid joint pain the same thing as gout?
Not necessarily. Gout is crystal disease with a specific presentation, while a high uric acid level can also sit inside a broader metabolic and inflammatory pattern without a gout flare. Distinguishing the two is a clinical question, not a lab-value question, and it is part of what the Clinical Evaluation is for.
What gets measured besides uric acid?
In the NHANES analysis that built the uric acid-inflammation-metabolism score, seven variables were retained: uric acid, eGFR, serum creatinine, hs-CRP, waist circumference, HDL cholesterol, and BMI. That mix, kidney handling plus inflammation plus body composition and lipids, is the reason uric acid is not read on its own; our own panel is described in The Metabolic Audit.
Does lowering my uric acid prevent osteoarthritis?
That is not what the data show. The NHANES analysis is cross-sectional, so it establishes an association between a combined score and osteoarthritis prevalence at a point in time, not a treatment effect. Anyone telling you a lab number is a target with a promised joint outcome is going past the evidence, and more of our writing on that gap sits in the Regen.MD library.
Do I have to do the metabolic work before a joint procedure?
Yes. Metabolic optimization is the mandatory first phase for every structural patient at Regen.MD; the metabolic bottleneck is corrected before any joint, spine, or nerve procedure is scheduled. That sequence is the practice’s standing policy, not a case-by-case preference. We see patients at 4477 Woodson Rd, Suite 103, St. Louis, MO 63134, listed on our locations page.
Sources
- Lu C, Yang Z, Ji Y, Song Z, Wei L, Wang X. “Development and validation of a uric acid-inflammation-metabolism score for predicting osteoarthritis risk: evidence from NHANES 2007–2018 and an external Chinese cohort.” Frontiers in Endocrinology (Lausanne), 2026 Jun 18;17:1861185. https://pmc.ncbi.nlm.nih.gov/articles/PMC13322868/
- Bowden RG, Richardson KA, Richardson LT. “Uric acid and metabolic syndrome: findings from National Health and Nutrition Examination Survey.” Frontiers in Medicine (Lausanne), 2022 Dec 14;9:1039230. https://pmc.ncbi.nlm.nih.gov/articles/PMC9795410/
- Zhang JF, Cheng I-H, Cheng-Chung J, et al. “Global burden of gout in the working-age population (15–64 years), 1990–2021: a systematic analysis of the Global Burden of Disease Study 2021.” medRxiv preprint, posted January 30, 2026 (not peer reviewed). https://www.medrxiv.org/content/10.64898/2026.01.30.26345202v1